Product Placement Produces High ROI

Small medical device firms don’t spend much time worrying about advertising. When working within tight budget constraints, a 30-second spot is a luxury most emerging firms can’t afford. But product placement may be an opportunity for smaller companies to get their products in front of a...

Accuray and CyberHeart Cut a Deal

Accuray, of Sunnyvale, CA, and Menlo Park, CA-based CyberHeart have inked a deal by which CyberHeart will use Accuray’s technology to develop a non-invasive method for performing cardiac ablation. Long-term visions for the developed technology also include applications to treat atrial...

Greatbatch to Buy Enpath for $102 Million

Greatbatch, of Clarence, NY, said today that it would acquire Minneapolis-based Enpath Medical for $102 million. The purchase, which includes assumption of debt (about $5.5 million worth, according to the Associate Press), gives Greatbatch an increased presence in the cardiac rhythm management and...

NFL Stars Back New Supplement Delivery System

HealthSport, an Amherst, NY-based company that makes an edible film strip delivery system for nutritional supplements, has raised $3 million in a private placement. The money, part of which came from three National Football League stars turned investors — Bruce Smith and Jim Kelly, formerly of the...

New Eye Mask for Growing Blepharoplasty Market

BioElectronics Corporation, a Frederick, MD-based company that makes anti-inflammatory patches to accelerate healing after surgery, has come out with a new eye mask to hold in place its ActiPatch therapy on patients who have had eyelid surgery. The mask, made of a soft, breathable fabric, has a pocket on...

Coherex Closing in on NMT and AGA in PFO Market

Red Herring yesterday ran an article about a three-way race to develop an FDA-approved PFO closure device. In the running are Coherex Medical, NMT Medical and AGA Medical. A PFO, or patent foramen ovale, is an opening in the upper chambers of the heart. All infants are born with foramen ovales, but the...

Westaim Management to Look at ‘Strategic Alternatives’

Reeling from its weakened share price, Westaim Corporation, a Canadian company that makes wound care and pharmaceutical products from nanotechnology, is taking a closer look at its business strategy. In light of unimpressive stock performance — Westaim has been trading at less than $1, down from...

High Hopes for New Prostate-Cancer Test

Results released today from a study of a new test for prostate cancer have raised spirits in the medical community and at the private Seattle firm that discovered it. Onconome‘s blood test measures EPCA-2 (Early Prostate Cancer Antigen), a newly discovered blood protein that when elevated, appears to...